Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-Media Thickness (CIMT), in Overweight Patients With Additional Risk Factors.

Trial Profile

Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-Media Thickness (CIMT), in Overweight Patients With Additional Risk Factors.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 May 2016

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms AUDITOR
  • Most Recent Events

    • 24 May 2011 Primary endpoint 'carotid intima-media thickness' has not been met, according to results published in Heart.
    • 24 May 2011 Results published in Heart.
    • 21 Jul 2009 Actual patient number (661) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top